Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

HHS Action On Drug Pricing: Here's Who Secretary Price Is Listening To

May 25 2017

• By Cathy Kelly

HHS Secretary Tom Price

Related Content

CMS Sticks With Combining Biosimilars In Single Medicare Payment Code

Oct 30 2015

REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill

Apr 30 2017

Trump's Medicaid Funding Change Could Alter Drug Access, Rebates

May 24 2017

MedPAC Wants To Boost Generic Use By Low-Income Part D Enrollees Via Lower Copays

Dec 16 2011

Medicaid Drug Formulary Ideas Floated, But US Manufacturers Are Skeptical

Mar 02 2017

Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund

May 03 2017

The Latest Furor Over Trump’s Drug Pricing Plan

May 16 2017

Value-Based Contracting Needs Federal Safe Harbors To Flourish, Lilly Says

Jun 15 2016

Related Companies

Sanofi

GSK plc

CVS Health Corp.

Cigna Corp.

Amgen, Inc.

Bristol Myers Squibb Company

Additional Topics

United States Pricing Debate Medicaid Policy BioPharmaceutical

More from Pricing Debate

More from Market Access

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window